Jun 15, 2022Halia Therapeutics Announces First Participant Dosed in Phase 1 Clinical Study of HT-6184
Mar 30, 2022Halia Therapeutics Presented Data on Targeting the NLRP3 Inflammasome in Alzheimer's Disease
